CSPC Pharmaceutical Group received clinical trial clearance from China’s National Medical Products Administration (NMPA) to test JMT‑206 for weight management in people with obesity or overweight plus at least one weight‑related comorbidity. The clearance allows CSPC to initiate first‑in‑human studies in China and move the program into formal clinical development. Marketed and investigational obesity agents are under intense regulatory and commercial scrutiny; CSPC’s clearance positions JMT‑206 to enter a crowded but high‑value therapeutic category in the Chinese market.